ALAoran Liu

Aoran Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aoran Liu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Lirong Yan

    The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China

    3 shared publications
  • Qian Xu

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    3 shared publications
  • Yuan Yuan

    Tumor Etiology and Screening Department of Cancer Institute, and Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Department, the First Hospital of China Medical University, Shenyang, China

    3 shared publications
  • Ye Zhang

    The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China

    2 shared publications
  • Ang Wang

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Hospital of China Medical University, Shenyang 110001, China

    1 shared publication
  • Boyan Zhang

    Department of Pharmacy The First Hospital of China Medical University Shenyang Liaoning P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

    by Na Ta, Shuyi Wang, Boyan Zhang, Ning Liu, Yingchen Han, Aoran Liu, Ying Xu, Tingsong Chen, Ye Zhang, Qiuhua Luo, et al.

    Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) are associated with a significantly poor prognosis and limited treatment options. Single‐cell RNA sequencing (scRNA‐seq) has revealed senescent Kupffer cells (sKCs), which are characterized by high levels of p21 expression and enriched in the tumor microenvironment (TME) of HCC‐PVTT. These sKCs exhibit a pronounced senescence‐associated secretory phenotype (SASP), promoting the proliferation and invasion of tumors and crosstalk with cancer‐associated fibroblasts. To target sKCs, a biomimetic nanodelivery system termed SKEV@AAV has been developed. This system comprises adeno‐associated virus (AAV) vectors carrying p21 ‐specific shRNA, encapsulated within sKCs‐derived exosomes (SKEV). SKEV@AAV effectively downregulated p21 , suppressed SASP signaling, and disrupted pro‐tumor interactions between sKCs and cancer‐associated fibroblasts. In an orthotopic PVTT model, SKEV@AAV showed single‐agent antitumor activity and attenuated SASP‐associated inflammatory remodeling. Furthermore, the combination efficacy with anti‐PD‐1 was evaluated in a murine splenic liver‐metastasis model, where SKEV@AAV reduced tumor burden, enhanced CD8 + T‐cell infiltration, decreased regulatory T cells, and promoted memory T‐cell differentiation. Our findings reveal a pivotal role of sKCs in mediating immune suppression in HCC‐PVTT and provide a nanotherapeutic strategy that reverses sKCs' senescence, reprograms the TME, and ultimately enhances antitumor immune activation.

  • Cannabidiol Reprograms Glucose Metabolism in Colorectal Adenocarcinoma by Targeting HIF-1α/LDHA Pathway

    by Yuzhe Zhang, Zhengtao Gao, Yanke Li, Lulu Zhang, Lirong Yan, Aoran Liu, Fang Li, Xiaoli Peng, Ruipeng Li, Yan Wang, et al.

    Colon adenocarcinoma (COAD) is characterized by the metabolic reprogramming, such as the Warburg effect, which drives tumor progression and immunosuppression. Hypoxia-inducible factor 1[ ] (HIF-1[ ] and lactate dehydrogenase A (LDHA) are critical regulators of this metabolic shift, but existing therapies are insufficiently specific to it. This study investigates the antitumor mechanisms of cannabidiol, a non-psychoactive phytocannabinoid, by using integrative multi-omics and functional validation. Single-cell transcriptomics revealed that cannabidiol reduced tumor cell proportions and suppressed glycolytic activity in COAD. Network pharmacology identified PTGS2 as a central target, with proteomic data confirming its overexpression in COAD tissues and association with poor prognosis. In vitro, cannabidiol inhibited COAD cell proliferation, migration, and colony formation while downregulating HIF-1[ ], LDHA, and GLUT1 expression. Metabolic assays demonstrated associated dose-dependent reductions in ATP production, glucose uptake, and lactate levels. Rescue experiments using the HIF-1[ ] agonist DMOG partially reversed cannabidiol’s antiglycolytic and antitumor effects, and thus confirmed pathway dependency. Synergy with the glycolysis inhibitor 2-DG enhanced therapeutic efficacy, which highlighted cannabidiol’s potential to overcome metabolic resistance. These findings establish cannabidiol as a novel inhibitor of HIF-1[ ]/LDHA-driven glycolysis, and thus provide a translational strategy for metabolic vulnerability in COAD.


  • Open Access

    Decrease in GPSM2 mediated by the natural product luteolin contributes to colon adenocarcinoma treatment and increases the sensitivity to fluorouracil

    by Chunjiao Yang, Lina Wu, Xin Jin, Aoran Liu, Zhitao Jing, Chuhan Feng, Zhengting Guo, Yuzhe Zhang, Yanju Ma, Fang Li, et al.


  • Open Access

    Pepsinogen C Interacts with IQGAP1 to Inhibit the Metastasis of Gastric Cancer Cells by Suppressing Rho-GTPase Pathway

    by Hanxi Ding, Yingnan Liu, Xiaodong Lu, Aoran Liu, Qian Xu, Yuan Yuan

    Aim: This study systematically explored the biological effects and mechanisms of PGC on gastric cancer (GC) cells in vitro and in vivo. Method: The critical biological roles of PGC in GC were assessed via EdU staining, Hoechst staining, flow cytometry, mouse models, CCK-8, wound healing, transwell, and sphere-forming assays. The interaction study with IQ-domain GTPase-activating protein 1 (IQGAP1) was used by Liquid chromatography-mass spectrometry co-immunoprecipitation, immunofluorescence staining, CHX-chase assay, MG132 assay, and qRT-PCR. Results: PGC inhibited the proliferation, viability, epithelial–mesenchymal transition, migration, invasion, and stemness of GC cells and promoted GC cell differentiation. PGC suppressed subcutaneous tumor growth and peritoneal dissemination in vivo. The interaction study found PGC inhibits GC cell migration and invasion by downregulating IQGAP1 protein and IQGAP1-mediated Rho-GTPase signaling suppression. In addition, PGC disrupts the stability of the IQGAP1 protein, promoting its degradation and significantly shortening its half-life. Moreover, the expression levels of PGC and IQGAP1 in GC tissues were significantly negatively correlated. Conclusion: PGC may act as a tumor suppressor in the development and metastasis of GC. PGC can downregulate its interacting protein IQGAP1 and inhibit the Rho-GTPase pathway, thereby participating in the inhibition of GC cell migration and invasion.


  • Open Access

    Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression

    by Yizhi Li, Aoran Liu, Songyi Liu, Lirong Yan, Yuan Yuan, Qian Xu

    The expression of CXC motif chemokine 17 (CXCL17) and its reported membrane receptor G-protein-coupled receptor 35 (GPR35) in different gastric pathological lesions and their clinical implications are largely unknown. In this study, a total of 860 pathological sections were immune-stained with either anti-CXCL17 or anti-GPR35 antibodies. Their expression was scored within the area of the normal gastric gland of non-atrophic gastritis (NAG-NOR), intestinal metaplasia of atrophic gastritis (AG-IM), IM adjacent to GC (GC-IM), and GC tissue. The clinical significance and potential function of CXCL17 and GPR35 were explored using multiple methods. Our results suggested that CXCL17 expression was gradually upregulated during the pathological progress of gastric diseases (NAG-NOR < AG-IM < GC-IM), but significantly downregulated when GC occurred. GPR35 had a similar expression pattern but its expression in GC remained abundant. High CXCL17 expression in GC was associated with less malignant behavior and was an independent biomarker of favorable prognosis. Overexpressing CXCL17 in HGC27 cells significantly upregulated CCL20 expression. TCGA analysis identified that CXCL17 was negatively correlated with some cancer-promoting pathways and involved in inflammatory activities. CTRP analysis revealed that gastric cell lines expressing less CXCL17 and were more sensitive to the CXCR2 inhibitor SB-225002.


  • Open Access

    Comprehensive Analysis and Validation of Solute Carrier Family 25 (SLC25) and Its Correlation with Immune Infiltration in Pan‐Cancer

    by Ao-Ran Liu, Ying-Nan Liu, Shi-Xuan Shen, Li-Rong Yan, Zhi Lv, Han-Xi Ding, Ang Wang, Yuan Yuan, Qian Xu

    As the largest gene family functioning in protein transport among human solute carriers, the SLC25 family (mitochondrial carrier family) can participate in development of cancer. However, a comprehensive exploration for the exactly roles of SLC family remains lacking. In the present study, a total of 15 functional SLC25 family genes were retrieved from all current publications. And multidimensional analyses were systematically performed based on the transcriptome and genome data of SLC25 family from a variety of online databases for their expression, immune cell infiltration, and cancer prognosis. Validation by qPCR and immunohistochemistry were further conducted for the expression of partial SLC25 family members in some tumor tissue. We found that the SLC25 family had strong correlation with immune cells, such as macrophages M2, CD8+ T cell, CD4+ T cell memory activated, and memory resting. Among them, SLC25A6 was most correlated with Macrophage M1 in uveal melanoma (r = −0.68, P = 1.9e − 0.5). Expression of mRNA level showed that SLC25A4 was downregulated in stomach adenocarcinoma and colon adenocarcinoma. SLC25A7 was highly expressed in stomach adenocarcinoma and colon adenocarcinoma. SLC25A23 was decreased in colon adenocarcinoma. qPCR and immunohistochemistry validation results were consistent with our bioinformatics prediction. SLC25A8 was associated with the prognosis of cancer. All these findings suggested that the SLC25 family might affects the immune microenvironment of the cancer and then had the potential to be predictive biomarkers for early diagnosis and prognosis as well as novel targets for individualized treatment of cancer.